New drug duo takes on deadly brain tumors in early trial
NCT ID NCT06630260
First seen Jan 22, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This trial tests two experimental drugs, avutometinib and defactinib, alone or with chemotherapy, in adults with aggressive brain tumors like glioblastoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 182 participants will join this early-phase study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Drug Development Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Neuro-Oncology Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.